Cargando…
Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
British Journal of Cancer (2002) 86, 1017–1018. DOI: 10.1038/sj/bjc/6600164 www.bjcancer.com © 2002 Cancer Research UK
Autores principales: | Andres, R, Mayordomo, J I, Isla, D, Marti, J L, Escudero, P, Filipovich, E, Saenz, A, Alvarez, I, Polo, E, Tres, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364159/ https://www.ncbi.nlm.nih.gov/pubmed/11953839 http://dx.doi.org/10.1038/sj.bjc.6600164 |
Ejemplares similares
-
Comparison of Doxorubicin Plus Docetaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine in Primary Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011) -
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
por: Bonneterre, J, et al.
Publicado: (2002) -
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022) -
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015) -
Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)